845 related articles for article (PubMed ID: 27658522)
21. Evaluating Emergency Department Opioid Prescribing Behaviors After Education About Mandated Use of the Pennsylvania Prescription Drug Monitoring Program.
Martello J; Cassidy B; Mitchell A
J Addict Nurs; 2018; 29(3):196-202. PubMed ID: 30180006
[TBL] [Abstract][Full Text] [Related]
22. Prescription Drug Monitoring Program: Registration and Use by Prescribers and Pharmacists Before and After Legal Mandatory Registration, California, 2010-2017.
Shev AB; Wintemute GJ; Cerdá M; Crawford A; Stewart SL; Henry SG
Am J Public Health; 2018 Dec; 108(12):1669-1674. PubMed ID: 30359105
[TBL] [Abstract][Full Text] [Related]
23. The utility of a statewide prescription drug-monitoring database vs the Current Opioid Misuse Measure for identifying drug-aberrant behaviors in emergency department patients already on opioids.
Wilson MP; Cucciare MA; Porter A; Chalmers CE; Mullinax S; Mancino M; Oliveto AH
Am J Emerg Med; 2020 Mar; 38(3):503-507. PubMed ID: 31221474
[TBL] [Abstract][Full Text] [Related]
24. Optimal Implementation of Prescription Drug Monitoring Programs in the Emergency Department.
Elder JW; DePalma G; Pines JM
West J Emerg Med; 2018 Mar; 19(2):387-391. PubMed ID: 29560070
[TBL] [Abstract][Full Text] [Related]
25. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
Lee B; Zhao W; Yang KC; Ahn YY; Perry BL
JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816
[TBL] [Abstract][Full Text] [Related]
26. How, why, and for whom do emergency medicine providers use prescription drug monitoring programs?
Smith RJ; Kilaru AS; Perrone J; Paciotti B; Barg FK; Gadsden SM; Meisel ZF
Pain Med; 2015 Jun; 16(6):1122-31. PubMed ID: 25688454
[TBL] [Abstract][Full Text] [Related]
27. Effect Of A "No Superuser Opioid Prescription" Policy On ED Visits And Statewide Opioid Prescription.
Kahler ZP; Musey PI; Schaffer JT; Johnson AN; Strachan CC; Shufflebarger CM
West J Emerg Med; 2017 Aug; 18(5):894-902. PubMed ID: 28874942
[TBL] [Abstract][Full Text] [Related]
28. Attitudes and self-reported practices of orthopedic providers regarding prescription opioid use.
Kattail D; Hsu A; Yaster M; Vozzo PT; Gao S; Thompson JM; Roter DL; Laporte D; Henn RF; Fiadjoe JE; Monitto CL
J Opioid Manag; 2019; 15(3):213-228. PubMed ID: 31343723
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Postoperative Opioid Prescriptions Before and After Implementation of a Mandatory Prescription Drug Monitoring Program.
Shenoy R; Wagner Z; Kirkegaard A; Romanelli RJ; Mudiganti S; Mariano L; Martinez M; Zanocco K; Watkins KE
JAMA Health Forum; 2021 Oct; 2(10):e212924. PubMed ID: 35977161
[TBL] [Abstract][Full Text] [Related]
30. Obstetrician-gynecologist perceptions and utilization of prescription drug monitoring programs: A survey study.
Goodin A; Bae J; Delcher C; Brown J; Roussos-Ross D
Medicine (Baltimore); 2021 Jan; 100(1):e24268. PubMed ID: 33429837
[TBL] [Abstract][Full Text] [Related]
31. National Estimates and Physician-Reported Impacts of Prescription Drug Monitoring Program Use.
Richwine C; Everson J
J Gen Intern Med; 2023 Mar; 38(4):881-888. PubMed ID: 36229762
[TBL] [Abstract][Full Text] [Related]
32. Who uses a prescription drug monitoring program and how? Insights from a statewide survey of Oregon clinicians.
Irvine JM; Hallvik SE; Hildebran C; Marino M; Beran T; Deyo RA
J Pain; 2014 Jul; 15(7):747-55. PubMed ID: 24787089
[TBL] [Abstract][Full Text] [Related]
33. A survey of Physicians' Perspectives on the New York State Mandatory Prescription Monitoring Program (ISTOP).
Blum CJ; Nelson LS; Hoffman RS
J Subst Abuse Treat; 2016 Nov; 70():35-43. PubMed ID: 27692186
[TBL] [Abstract][Full Text] [Related]
34. Barriers, solutions, and effect of using pharmacogenomics data to support opioid prescribing.
Bright D; Petry N; Roath E; Reckow E; Chavour S
J Manag Care Spec Pharm; 2020 Dec; 26(12):1597-1602. PubMed ID: 33252002
[TBL] [Abstract][Full Text] [Related]
35. "Doctor and pharmacy shopping": A fading signal for prescription opioid use monitoring?
Delcher C; Harris DR; Park C; Strickler GK; Talbert J; Freeman PR
Drug Alcohol Depend; 2021 Apr; 221():108618. PubMed ID: 33677354
[TBL] [Abstract][Full Text] [Related]
36. Changes in opioid and other analgesic prescribing following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis of early outcomes.
Nielsen S; Picco L; Russell G; Pearce C; Andrew NE; Lubman DI; Bell JS; Buchbinder R; Xia T
Int J Drug Policy; 2023 Jul; 117():104053. PubMed ID: 37209441
[TBL] [Abstract][Full Text] [Related]
37. The association between prescription drug monitoring programs and controlled substance prescribing: a cross-sectional study using data from 2019 National Electronic Health Records Survey.
Mehta S; Brown W; Ferguson E; Najera J; Pantell MS
J Am Med Inform Assoc; 2023 May; 30(6):1042-1046. PubMed ID: 37011637
[TBL] [Abstract][Full Text] [Related]
38. Prescription drug monitoring programs operational characteristics and fatal heroin poisoning.
Martins SS; Ponicki W; Smith N; Rivera-Aguirre A; Davis CS; Fink DS; Castillo-Carniglia A; Henry SG; Marshall BDL; Gruenewald P; Cerdá M
Int J Drug Policy; 2019 Dec; 74():174-180. PubMed ID: 31627159
[TBL] [Abstract][Full Text] [Related]
39. Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians.
Bao Y; Pan Y; Taylor A; Radakrishnan S; Luo F; Pincus HA; Schackman BR
Health Aff (Millwood); 2016 Jun; 35(6):1045-51. PubMed ID: 27269021
[TBL] [Abstract][Full Text] [Related]
40. Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: Evidence from the National Survey of Drug Use and Health.
Ali MM; Dowd WN; Classen T; Mutter R; Novak SP
Addict Behav; 2017 Jun; 69():65-77. PubMed ID: 28152391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
